Aptar Pharma Continues Global Expansion with North America Capacity Extension
Aptar announced the next phase of its global capacity expansion plan in North America, at its Aptar Congers, New York site. This investment will help Aptar meet the growing prescription and consumer healthcare customer demand for proprietary drug delivery systems in North America. The North America Capacity Extension will benefit local customers. Manufacturing began at Aptar Congers in 2002 with a cleanroom and the production of Aptar Pharma’s VP3 pumps, and today the site manufactures a wide range of proprietary drug delivery products for nasal and injectable delivery routes. To support increasing patient demand for systemic nasal delivery, Aptar Pharma is significantly expanding the manufacturing capacity of its proprietary Unidose (UDS) Nasal Spray Systems via the addition of molds and assembly lines in cleanroom manufacturing settings, with the additional capacity planned to come online in Q4 2024.